Total submissions: 35
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000199033 | SCV000059072 | pathogenic | Hypertrophic cardiomyopathy | 2020-04-14 | criteria provided, single submitter | clinical testing | proposed classification - variant undergoing re-assessment, contact laboratory |
Gene |
RCV000158104 | SCV000208039 | pathogenic | not provided | 2022-11-15 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); A study of fetal rat cardiomyocytes suggests that p.(E542Q) may have a dominant negative effect on sarcomere function (Flavigny et al., 1999); This variant is associated with the following publications: (PMID: 18533079, 30645170, 31198128, 23299917, 22057632, 15519027, 20378854, 19150014, 12707239, 18761664, 16199542, 21839045, 24793961, 20433692, 24093860, 25637381, 25031304, 27483260, 9048664, 26441228, 26936621, 28658286, 28538763, 28611029, 28193612, 28408708, 28790153, 28615295, 27532257, 28679633, 29511324, 29121657, 30609409, 29790872, 31006259, 31514951, 31996869, 31447099, 26822237, 24704860, 33500567, 31589614, 32731933, 32686758, 33673806, 34135346, 34495297, 34097875, 10610770) |
Invitae | RCV000199033 | SCV000253809 | pathogenic | Hypertrophic cardiomyopathy | 2024-01-31 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 542 of the MYBPC3 protein (p.Glu542Gln). This variant also falls at the last nucleotide of exon 17, which is part of the consensus splice site for this exon. This variant is present in population databases (rs121909374, gnomAD 0.003%). This missense change has been observed in individuals with hypertrophic cardiomyopathy (HCM) (PMID: 9048664, 9631872, 15519027, 16199542, 18533079, 20433692, 25031304, 27532257). It has also been observed to segregate with disease in related individuals. This variant is also known as c.1679G>C. ClinVar contains an entry for this variant (Variation ID: 8608). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this missense change alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 9048664, 22057632, 25031304). For these reasons, this variant has been classified as Pathogenic. |
Agnes Ginges Centre for Molecular Cardiology, |
RCV000201915 | SCV000256661 | pathogenic | Hypertrophic cardiomyopathy 1 | 2015-06-30 | criteria provided, single submitter | research | The MYBPC3 Glu542Gln has previously been reported in multiple unrelated HCM cases (see references). Studies have shown the variant to co-segregate with disease in familial HCM (Carrier et al, 1997; Saltzman et al, 2010) however, we note that Saltzman et al. (2010) also identified an additional known disease-causing variant (MYBPC3 Arg502Trp). We have identified this variant in 4 unrelated HCM probands in our cohort. Familial segregation was performed where possible and was found to segregate with disease in a total of 6 individuals (2 in one family, 4 in another family). MYBPC3 Glu542Gln is a rare variant with a minor allele frequency of 0.00002485 in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/). The variant affects the last nucleotide of exon 17 and has been shown to impact splicing (exon 17 skip) and result in an aberrant transcript (Carrier et al, 1997; Crehalet et al, 2012). In silico tools (SIFT, PolyPhen2, MutationTaster) are supportive of this variant having a disease-causing effect. Furhermore, loss-of-function variants in MYBPC3 including splice variants, are an established mechanism of disease in HCM. Based on the observation of MYPBC3 Glu542Gln in multiple HCM patients in independent studies and our cohort, its rarity in the general population, and our familial segregation analyses, we classify this variant as "pathogenic". |
Ambry Genetics | RCV000247235 | SCV000319843 | pathogenic | Cardiovascular phenotype | 2021-10-22 | criteria provided, single submitter | clinical testing | The c.1624G>C pathogenic mutation (also known as p.E542Q), located in coding exon 17 of the MYBPC3 gene, results from a G to C substitution at nucleotide position 1624. This change occurs in the last base pair of coding exon 17, which makes it likely to have some effect on normal mRNA splicing. In addition to potential splicing impact, this alteration changes the glutamic acid at codon 542 to glutamine, an amino acid with highly similar properties. Studies using cDNA from patient lymphocytes have reported the mutation resulted in skipping of exon 17, leading to a premature stop codon (Carrier L et al. Circ Res. 1997;80(3):427-34; Singer ES et al. Circ Genom Precis Med. 2019 01;12(1):e002368). Another in vitro study evaluated mRNA from human cardiac muscle in patients with this mutation and showed one full-length missense mutant mRNA product and one nonsense mRNA product resulting from skipping of exon 17 (alteration reported as c.1679G>C) (Marston S et al. J Muscle Res Cell Motil. 2012;33(1): 75-80). This mutation has been reported in multiple individuals with hypertrophic cardiomyopathy (HCM) and shown to segregate with disease in at least three families (Carrier L et al. Circ Res. 1997;80(3):427-34; García-Castro M et al. Rev Esp Cardiol. 2009;62(1):48-56; Rodríguez-García MI et al. BMC Med Genet. 2010;11:67; Ross SB et al. Circ Cardiovasc Genet, 2017 Jun;10:[Epub ahead of print]). This alteration was reported in families who also had a second mutation in MYBPC3 and presented with severe HCM or sudden death (Saltzman AJ et al. Circ Res. 2010;106(9):1549-52; Rafael JF et al. Arq. Bras. Cardiol. 2017 Apr;108(4):354-360). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
Center of Genomic medicine, |
RCV000009139 | SCV000494449 | pathogenic | Hypertrophic cardiomyopathy 4 | 2016-03-30 | criteria provided, single submitter | clinical testing | |
Hudson |
RCV000009139 | SCV000584103 | pathogenic | Hypertrophic cardiomyopathy 4 | 2015-12-10 | criteria provided, single submitter | research | |
Phosphorus, |
RCV000009139 | SCV000679775 | pathogenic | Hypertrophic cardiomyopathy 4 | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000247235 | SCV000696317 | pathogenic | Cardiovascular phenotype | 2016-09-19 | criteria provided, single submitter | clinical testing | Variant summary: The MYBPC3 c.1624G>C (p.Glu542Gln) variant involves the alteration of the conserved last nucleotide of exon 17. 2/3 in silico tools predict a benign outcome for this variant (SNPs&GO not captured due to low reliability index). 5/5 splice prediction tools predict the complete loss or reduction in cannonical splice donor site. Functional studies have confirmed that this variant causes the skipping of exon 17 and truncated protein product (Carrier_1997, Marston_2012, Helms_2014). This variant was found in 2/81374 control chromosomes at a frequency of 0.0000246, which does not exceed the estimated maximal expected allele frequency of a pathogenic MYBPC3 variant (0.0010005). The variant has been reported in numerous affected individuals in the literature, including family members in which the variant segregated with disease. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. |
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, |
RCV000627130 | SCV000747943 | pathogenic | Primary familial dilated cardiomyopathy | 2017-04-24 | criteria provided, single submitter | clinical testing | |
Hudson |
RCV000009139 | SCV000993585 | pathogenic | Hypertrophic cardiomyopathy 4 | 2019-10-10 | criteria provided, single submitter | research | |
Biesecker Lab/Clinical Genomics Section, |
RCV000009139 | SCV001132521 | pathogenic | Hypertrophic cardiomyopathy 4 | 2019-03-28 | criteria provided, single submitter | curation | |
CHEO Genetics Diagnostic Laboratory, |
RCV001170957 | SCV001333612 | pathogenic | Cardiomyopathy | 2023-03-17 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV001170957 | SCV001343368 | pathogenic | Cardiomyopathy | 2023-02-23 | criteria provided, single submitter | clinical testing | This variant changes the last nucleotide c.G of the Ig-like domain C3 of exon 17 of the MYBPC3 gene and is predicted to impair RNA splicing at the intron 17 splice donor site. RNA studies have shown that this variant causes skipping of exon 17 and introduces a premature translation stop codon (PMID: 9048664, 22057632, 25031304, 34097875). An experimental functional study has shown that the truncated protein causes decreased protein incorporation into the sarcomere (PMID: 10610770). This variant has been reported in over 50 individuals affected with hypertrophic cardiomyopathy (PMID: 9048664, 9631872, 12707239, 15519027, 16199542, 18533079, 19150014, 20433692, 25031304, 27483260, 27532257) and segregated with disease in 6 affected relatives across 2 families (PMID: 9048664). This variant has been identified in 5/262678 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MYBPC3 function is a known mechanism of disease. Based on available evidence, this variant is classified as Pathogenic. |
Human Genome Sequencing Center Clinical Lab, |
RCV000009139 | SCV001434956 | pathogenic | Hypertrophic cardiomyopathy 4 | 2019-10-30 | criteria provided, single submitter | clinical testing | The c.1624G>C (p.Glu542Gln) variant in exon 17 of the MYBPC3 gene has been reported in multiple unrelated individuals with hypertrophic cardiomyopathies (HCM) (PMID: 9631872, 12707239, 15519027, 16199542, 16858239, 19150014, 20738943, 21239446, 18533079, 24093860, 27483260, 27532257). It has also been reported to segregate with disease in multiple affected individuals from unrelated families (PMID: 9048664, 20433692). This variant has an extremely low frequency in general population databases. The c.1624G>C sequence change is located at the last base of the exon and predicted to alter gene splicing. mRNA studies using patient lymphocytes and cardiac tissues have confirmed that this variant causes skipping of exon 17, introducing a premature translational termination codon, while normally spliced missense transcript for c.1624G>C (p.Glu542Gln) is also expressed (PMID: 9048664, 22057632, 25031304, 28679633). Functional studies in fetal rat cardiomyocytes showed that incorporation of truncating variants of MYBPC3 into sarcomere is reduced compared to wild-type and suggested that truncating variants and the c.1624G>C (p.Glu542Gln) missense variant have a dominant negative effect on the myobrillar architecture (PMID: 10610770). In summary, this c.1624G>C (p.Glu542Gln) variant in the MYBPC3 gene is classified as pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV000158104 | SCV001447952 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Rady Children's Institute for Genomic Medicine, |
RCV000009139 | SCV001984871 | pathogenic | Hypertrophic cardiomyopathy 4 | 2020-07-07 | criteria provided, single submitter | clinical testing | This variant affects the last nucleotide of exon 17 of MYBPC3 and is likely to interfere with native splicing. This variant has been previously reported mainly as a heterozygous variant in unrelated families with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), and also as a compound heterozygous change in patients with HCM (PMID: 29121657, 27532257, 31514951, 16199542, 20378854). Expression studies using mRNA from patient myocardial tissue demonstrate that this variant leads to exon skipping (PMID: 25031304) and decreased protein incorporation into the A-band of the sarcomere (PMID: 10610770). It is present in the heterozygous state in the gnomAD population database at a frequency of 0.002% (5/262678) and thus is presumed to be rare. The c.1624G>C (p.Glu542Gln) variant is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.1624G>C (p.Glu542Gln) variant is classified as Pathogenic. |
Revvity Omics, |
RCV000158104 | SCV002017652 | pathogenic | not provided | 2022-09-27 | criteria provided, single submitter | clinical testing | |
Ai |
RCV000158104 | SCV002503365 | pathogenic | not provided | 2022-02-08 | criteria provided, single submitter | clinical testing | |
Hudson |
RCV000009139 | SCV002762765 | pathogenic | Hypertrophic cardiomyopathy 4 | 2022-11-09 | criteria provided, single submitter | research | ACMG codes:PVS1_VeryStrong, PS3_Supporting, PS4_Moderate, PM2_Moderate, PP1_Strong |
Fulgent Genetics, |
RCV000505586 | SCV002814679 | pathogenic | Hypertrophic cardiomyopathy 4; Left ventricular noncompaction 10 | 2022-03-25 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003332998 | SCV004040644 | pathogenic | Left ventricular noncompaction 10 | 2023-03-29 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000009139 | SCV004040787 | pathogenic | Hypertrophic cardiomyopathy 4 | 2023-03-29 | criteria provided, single submitter | clinical testing | |
Greenwood Genetic Center Diagnostic Laboratories, |
RCV003387501 | SCV004099224 | pathogenic | MYBPC3-related disorder | 2023-07-19 | criteria provided, single submitter | clinical testing | PM2, PP1, PS3_VeryStrong |
Illumina Laboratory Services, |
RCV000009139 | SCV004101361 | pathogenic | Hypertrophic cardiomyopathy 4 | 2023-08-24 | criteria provided, single submitter | clinical testing | The MYBPC3 c.1624G>C (p.Glu542Gln) missense variant has been identified in individuals with hypertrophic cardiomyopathy (PMID: 9048664; 9631872; 27532257; 30645170; 36264615). This variant has been shown to segregate with disease in at least two families (PMID: 9048664). The p.Glu542Gln variant is not observed at a significant frequency in version 2.1.1 or version 3.1.2 of the Genome Aggregation Database. Functional studies conducted in patient cells and non-human cells demonstrate that this variant results in abnormal splicing of exon 17 leading to a truncated protein that lacks the titin and myosin binding sites (PMID: 9048664; 25031304; 30645170; 34097875). Based on the available evidence, the c.1624G>C (p.Glu542Gln) variant is classified as pathogenic for hypertrophic cardiomyopathy. |
Clinical Genomics Laboratory, |
RCV000009139 | SCV004177148 | pathogenic | Hypertrophic cardiomyopathy 4 | 2023-08-02 | criteria provided, single submitter | clinical testing | The MYBPC3 c.1624G>C (p.Glu542Gln) variant has been observed in individuals with hypertrophic cardiomyopathy and has been shown to segregate with disease in affected families (Carrier L et al., PMID: 9048664; Charron P et al., PMID: 9631872; Van Driest L et al., PMID: 15519027; Ingles J et al., PMID: 16199542; Olivetto I et al., PMID: 18533079; Rodríguez-García M et al., PMID: 20433692; Helms A et al., PMID: 25031304; Walsh R et al., PMID: 27532257). Functional studies show that this misssense variant, which sits next to a consensus splice site, alters splicing and results in nonsense mediated decay (Carrier L et al., PMID: 9048664; Martson S et al., PMID: 22057632; Helms A et al., PMID: 25031304). This variant is only observed on 5/262,678 alleles in the general population (gnomAD v.2.1.1), indicating it is not a common variant. Computational predictors indicate that the variant is damaging, evidence that correlates with impact to MYBPC3 function. Based on available information, and based on ACMG/AMP guidelines for variant interpretation (Richards S et al., PMID: 25741868), this variant is classified as pathogenic. |
Mayo Clinic Laboratories, |
RCV000158104 | SCV004226848 | pathogenic | not provided | 2023-06-16 | criteria provided, single submitter | clinical testing | PP1, PS3, PS4 |
OMIM | RCV000009139 | SCV000029356 | pathogenic | Hypertrophic cardiomyopathy 4 | 1997-03-01 | no assertion criteria provided | literature only | |
CSER _CC_NCGL, |
RCV000035424 | SCV000190378 | pathogenic | Primary familial hypertrophic cardiomyopathy | 2014-06-01 | no assertion criteria provided | research | |
Blueprint Genetics | RCV000035424 | SCV000207041 | pathogenic | Primary familial hypertrophic cardiomyopathy | 2014-10-27 | no assertion criteria provided | clinical testing | |
Stanford Center for Inherited Cardiovascular Disease, |
RCV000158104 | SCV000280219 | likely pathogenic | not provided | 2013-11-04 | no assertion criteria provided | clinical testing | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. MYBPC3 p.Glu542Gln Based on the data reviewed below we classify this variant as likely disease causing. This variant has been observed in at least 13 individuals with HCM. It has been published in association with Hypertrophic Cardiomyopathy (HCM). We have also observed this variant in two other patients with HCM. Carrier et al (1997) reported the variant in two unrelated families with HCM with the variant segregating with HCM in 3 individuals in each family (same families reported in Charron et al 1998). Richard et al (2003) reported the variant in two unrelated individuals with HCM. Van Driest et al (2004) reported the variant in one case of HCM (likely reported again in Olivotto et al 2011). Ingles et al (2005) reported the variant in a patient with HCM who also had another variant in MYBPC3 (p.Ala851Val). Fokstuen et al (2011) reported the variant in an individual with HCM. Page et al (2012) reported one individual with HCM with this variant in their British cohort. Saltzman et al (2010) reported the variant in two unrelated individuals with HCM who also carried p.Arg502Trp in MYBPC3 from their American cohort. This is the most common HCM disease-causing variant in the US and we consider it very likely disease causing. These patients had more severe disease than the patients in their series with just p.Arg502Trp. Crehalet et al (2012) observed the variant in an individual with HCM from their French cohort (this appears to be a distinct case from the one previously reported by Carrier and Charron). The variant affects the last nucleotide of the exon, changing it from the consensus G to a C. Carrier et al (1997) examined cDNA and reported that this variant leads to skipping of exon 17 and introduction of a premature stop codon. In a myectomy sample from a patient with this variant Vydyanath et al (2012) observed skipping of exon 17 and a 28% deficiency of the myosin binding protein. Crehalet et al (2012) observed multiple aberrant splicing products in their in vitro experiments. The variant has been seen in 1 of ~ 6957 published controls and individuals from publicly available general population datasets. This variant has not been seen in a total of 650 published controls, including 200 individuals examined by van Driest et al (2004), 100 control individuals reported by Richard et al (2003), 150 control individuals reported by Ingles et al (2005) and 200 control individuals reported by Carrier et al (1997). The variant is listed in dbSNP (rs121909374) as variant associated with a Mendelian phenotype in OMIM but with no population frequency data (as of January 2nd, 2013). It is listed in the 1000 genomes data set, but only in reference to the dbSNP listing (as of January 2nd, 2013). The variant was reported online in 0 of 4208 Caucasian individuals and 1 of 2099 African-American individuals in the NHLBI Exome Sequencing Project dataset (as of April 4th, 2013). The phenotype of those individuals is not publicly available, however the cohorts that were merged to create this dataset were all either general population samples or samples recruited for common cardiovascular disease such as hypertension. Note that other variants with strong evidence for pathogenicity have been observed at this low frequency in this dataset. |
Donald Williams Parsons Laboratory, |
RCV000505586 | SCV000599924 | pathogenic | Hypertrophic cardiomyopathy 4; Left ventricular noncompaction 10 | 2014-06-09 | no assertion criteria provided | research | This variant has been previously reported as disease-causing. It was an incidental finding in our study, in a 3-year-old male with Wilms tumor. |
Bioscientia Institut fuer Medizinische Diagnostik Gmb |
RCV000009139 | SCV001468139 | pathogenic | Hypertrophic cardiomyopathy 4 | 2020-06-16 | no assertion criteria provided | clinical testing | |
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000158104 | SCV001954605 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000158104 | SCV001970359 | pathogenic | not provided | no assertion criteria provided | clinical testing |